BioSig Technologies to Present at the Fifth Annual OktoberINVESTfest, US – Bavaria, Germany Investors Conference In New York

BioSig Technologies, Inc., a medical device company developing the PURE EP(TM) System, a novel cardiac electrophysiology (EP) signal acquisition and analysis system, today announced it will present at the September 28th 2016, fifth annual OktoberINVESTfest, presented by Invest in Bavaria in partnership with Joseph Gunnar & Co. BioSig will present at 5:20 p.m. ET at the New York Academy of Sciences at 7 World Trade Center in New York.

OktoberINVESTFest brings together U.S. and German investors, innovators, industry leaders, and 43 select innovative U.S. and German small and microcap companies as well as some private growth and early stage investment opportunities. The resulting business and investment ties will deepen transatlantic relations and encourage economic and scientific exchange.

Keynoter Kevin Harris, Senior Economist and North American Director of Roubini Global Economics will lend insight into investing in Europe. Other spotlight talks include: Dr. Joann Halpern, Director of the German Center for Research and Innovation giving advice on European grant programs and research partnerships and the much awaited discussion on the Cancer MoonShot initiative by committee members: Dr. Dvorit Samid, Head of Global Oncology Medical Affairs Program at NantKwest and Dr David Sans, Head of Equity Research at Joseph Gunnar & Co. Likewise we will hear about Smart Factories and the Industrial internet from experts at IBM, Draper Labs and Bavarian global player Siemens.

“OktoberINVESTFest is an example of how Invest in Bavaria is continuously working to provide US companies with direct access to expansion opportunities in the State of Bavaria,” said Jan Danisman, Executive Director at Bavarian U.S. Offices for Economic Development. “At the same time, we are introducing innovative Bavarian companies to US investors and partners, thus working to solidify relationships between the two markets.”